Advertisement

Current Rheumatology Reports

, Volume 8, Issue 2, pp 145–150 | Cite as

The role of circulating fibrocytes in fibrosis

  • Timothy E. Quan
  • Shawn E. Cowper
  • Richard BucalaEmail author
Article

Abstract

Fibrocytes are cells that circulate in the peripheral blood and produce connective tissue proteins such as vimentin and collagens I and III. Fibrocytes are associated with skin lesions, pulmonary fibrosis, and tumors and they contribute to the remodeling response by secreting matrix metalloproteinases. Fibrocytes can further differentiate, and they are a likely source of the contractile myofibroblast that appears in many fibrotic lesions. There is evidence in the skin for a prominent role for fibrocytes in the development of hypertrophic scars and keloids. In asthma or in experimental models of pulmonary fibrosis, fibrocytes have been shown to infiltrate areas of inflammation and tissue damage. Fibrocytes constitute part of the stromal response to tumor invasion, and there is evidence that these cells may be a prognosticator of malignant potential. IL-1, TGF-β, chemokines, and serum amyloid P modulate the appearance and function of fibrocytes. Fibrocytes themselves produce inflammatory cytokines, growth factors, and chemokines. The intercellular signals that modulate fibrocyte trafficking, proliferation, and differentiation are only partially defined, but a better understanding of these signals enable new therapies to prevent pathologic fibrosis or to improve the tissue repair response.

Keywords

Scleroderma Basal Cell Carcinoma Cervical Intraepithelial Neoplasia Wound Repair Serum Amyloid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Chesney J, Bucala R: Peripheral blood fibrocytes. In In Human Cell Culture. Edited by Pallsson BO, Koller MR, Masters J. London: Kluwer Academic Publishers; 2001:209–219.Google Scholar
  2. 2.
    Bucala R, Spiegel LA, Chesney J, et al.: Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994, 1:71–81. First description of circulating fibrocytes.PubMedGoogle Scholar
  3. 3.
    Burkitt Y, Heath H: Wheater’s Functional Histology, vol 1, edn 3. London: Churchill Livingston; 1997.Google Scholar
  4. 4.
    Schmidt M, Sun G, Stacey MA, et al.: Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003, 71:380–389. First report of fibrocytes in human lung disease. Cells were identified in asthma patients.Google Scholar
  5. 5.
    Mori L, Bellini A, Stacey MA, et al.: Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res 2005, 304:81–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Fathke C, Wilson L, Hutter J, et al.: Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells 2004, 22:812–822.PubMedCrossRefGoogle Scholar
  7. 7.
    Hashimoto N, Jin H, Liu T, et al.: Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest 2004, 113:243–252.PubMedCrossRefGoogle Scholar
  8. 8.
    Opalenik SR, Davidson JM: Fibroblast differentiation of bone marrow-derived cells during wound repair. FASEB J 2005, 19:1561–1563.PubMedGoogle Scholar
  9. 9.
    Abe R, Donnelly SC, Peng T, et al.: Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001, 166:7556–7562. First identification of trafficking signals of fibrocytes in vivo.PubMedGoogle Scholar
  10. 10.
    Yang L, Scott PG, Giuffre J, et al.: Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest 2002, 82:1183–1192.PubMedGoogle Scholar
  11. 11.
    Labat ML, Bringuier AF, Arys-Philippart C, et al.: Monocytic origin of fibrosis. In vitro transformation of HLA-DR monocytes into neo-fibroblasts: inhibitory effect of all-trans retinoic acid on this process. Biomed Pharmacother 1994, 48:103–111.PubMedCrossRefGoogle Scholar
  12. 12.
    Moore BB, Kolodsick JE, Thannickal VJ, et al.: CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005, 166:675–684.PubMedGoogle Scholar
  13. 13.
    Phillips RJ, et al.: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004, 114(3):p. 438–46.PubMedCrossRefGoogle Scholar
  14. 14.
    Chesney J, Metz C, Stavitsky AB, et al.: Regulated production of type I collagen and inf lammator y cytokines by peripheral blood fibrocytes. J Immunol 1998, 160:419–425. Characterization of fibrocyte phenotype and effector function. Described fibrocytes in granuloma.PubMedGoogle Scholar
  15. 15.
    Robson RT, Smith DJ: Wounds and wound healing. In Essentials of Genereal Surgery. Edited by Lawrence P, Satterfield T. Baltimore: Williams and Wilkins; 1992:119–125.Google Scholar
  16. 16.
    Aiba S, Tagami H: Inverse correlation between CD34 expression and proline-4-hydroxylase immunoreactivity on spindle cells noted in hypertrophic scars and keloids. J Cutan Pathol 1997, 24:65–69.PubMedCrossRefGoogle Scholar
  17. 17.
    Yang L, Scott PG, Dodd C, et al.: Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen 2005, 13:398–404.PubMedCrossRefGoogle Scholar
  18. 18.
    Hartlapp I, Abe R, Saeed RW, et al.: Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001, 15:2215–2224.PubMedCrossRefGoogle Scholar
  19. 19.
    Barth PJ, Ebrahimsade S, Ramaswamy A, Moll R: CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions. Virchows Arch 2002, 440:298–303.PubMedCrossRefGoogle Scholar
  20. 20.
    Chauhan H, Abraham A, Phillips JR, et al.: There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J Clin Pathol 2003, 56:271–276.PubMedCrossRefGoogle Scholar
  21. 21.
    Ramaswamy A, Moll R, Barth PJ: CD34+ fibrocytes in tubular carcinomas and radial scars of the breast. Virchows Arch 2003, 443:536–540.PubMedCrossRefGoogle Scholar
  22. 22.
    Barth PJ, Ebrahimsade S, Hellinger A, et al.: CD34+ fibrocytes in neoplastic and inflammatory pancreatic lesions. Virchows Arch 2002, 440:128–133.PubMedCrossRefGoogle Scholar
  23. 23.
    Barth PJ, Ramaswamy A, Moll R: CD34(+) fibrocytes in normal cer vical stroma, cer vical intraepithelial neoplasia III, and invasive squamous cell carcinoma of the cer vix uteri. Virchows Arch 2002, 441:564–568.PubMedCrossRefGoogle Scholar
  24. 24.
    Kirchmann TT, Prieto VG, Smoller BR: CD34 staining pattern distinguishes basal cell carcinoma from trichoepithelioma. Arch Dermatol 1994, 130:589–592.PubMedCrossRefGoogle Scholar
  25. 25.
    Barth PJ, Schenckzu Schweinsberg T, Ramaswamy A, Moll R, et al.: CD34+ fibrocytes, alpha-smooth muscle antigen-positive myoflbroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx. Virchows Arch 2004, 444:231–234.PubMedCrossRefGoogle Scholar
  26. 26.
    Humphreys TR, Monteiro MR, Murphy GF: Mast cells and dendritic cells in basal cell carcinoma stroma. Dermatol Surg 2000, 26:200–203.PubMedCrossRefGoogle Scholar
  27. 27.
    Kirchmann TT, Prieto VG, Smoller BR: Use of CD34 in assessing the relationship between stroma and tumor in desmoplastic keratinocytic neoplasms. J Cutan Pathol 1995, 22:422–426.PubMedCrossRefGoogle Scholar
  28. 28.
    Aiba S, et al.: CD34+ spindle-shaped cells selectively disappear from the skin lesion of scleroderma. Arch Dermatol 1994, 130(5):p. 593–7.PubMedCrossRefGoogle Scholar
  29. 29.
    White B, et al.: Systemic sclerosis and related syndromes a epidemiology, pathology and pathogenesis. In Primer on the Rheumatic Diseases. Edited by Klippel J. Atlanta: Arthritis Foundation; 2001:354–357.Google Scholar
  30. 30.
    Pilling D, Buckley CD, Salmon M, Gomer RH: Inhibition of.brocyte differentiation by serum amyloid P. J Immunol 2003, 171:5537–5546. Interesting report linking SAP with fibrocyte differentiation and potential role in fibrosing disorder such as scleroderma.PubMedGoogle Scholar
  31. 31.
    Cowper SE, Su LD, Bhawan J, et al.: Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001, 23:383–393. First clinical description of NFD in patients.PubMedCrossRefGoogle Scholar
  32. 32.
    Nephrogenic Fibrosing Dermopathy[NFD website]. 2001- present, Cowper SE. http:/ www.pathmax.com/dermweb. Accessed December 1, 2005. National Registry for NFD.Google Scholar
  33. 33.
    Moschella SL, Kay J, Mackool BT, Liu V: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004, 351:2219–2227.PubMedCrossRefGoogle Scholar
  34. 34.
    Cowper SE: Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003, 15:785–790.PubMedCrossRefGoogle Scholar
  35. 35.
    Cowper SE, Bucala R: Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003, 25:358.PubMedCrossRefGoogle Scholar
  36. 36.
    Savage DD, Garrison RJ, Devereux RB, et al.: Mitral valve prolapse in the general population. 1. Epidemiologic features: the Framingham Study. Am Heart J 1983, 106:571–576.PubMedCrossRefGoogle Scholar
  37. 37.
    Freed L A, Levy D, Levine R A, et al.: Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 1999, 341:1–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Barth PJ, Koster H, Moosdorf R: CD34+ fibrocytes in normal mitral valves and myxomatous mitral valve degeneration. Pathol Res Pract 2005, 201:301–304.PubMedCrossRefGoogle Scholar
  39. 39.
    Paget J: Lectures on Surgical Pathology. In Royal College of Surgeons of England. London: Longmans; 1863.Google Scholar
  40. 40.
    Stirling GA, Kakkar V V: Cells in the circulating blood capable of producing connective tissue. Br J Exp Pathol 1969, 50:51–55.PubMedGoogle Scholar
  41. 41.
    Cowper SE, Bucala R: Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003, 25:358.PubMedCrossRefGoogle Scholar
  42. 42.
    Direkze NC, Hodivala-Dilke K, Jeffery R, et al.: Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004, 64:8492–8495.PubMedCrossRefGoogle Scholar
  43. 43.
    Nagy N, Biro E, Takacs A, et al.: Peripheral blood fibrocytes contribute to the formation of the avian spleen. Dev Dyn 2005, 232:55–66.PubMedCrossRefGoogle Scholar
  44. 44.
    Hong KM, Burdick MD, Phillips RJ, et al.: Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice. FASEB J 2005, 19:2029–2031.PubMedGoogle Scholar
  45. 45.
    Chesney J, Bacher M, Bender A, et al.: The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci U S A 1997, 94:6307–6312.PubMedCrossRefGoogle Scholar
  46. 46.
    Balmelli C, Ruggli N, McCullough K, Summerfield A, et al.:Fibrocytes are potent stimulators of anti-virus cytotoxic T cells. J Leukoc Biol 2005, 77:923–933.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Timothy E. Quan
  • Shawn E. Cowper
  • Richard Bucala
    • 1
    Email author
  1. 1.Department of Medicine, Sections of Rheumatology and DermatologyYale University School of MedicineNew HavenUSA

Personalised recommendations

Cite article

Buy options